Navigation Links
Irritable Bowel Syndrome Therapeutics Clinical Trials H1 2015 Review Report Available at RnRMarketResearch.com
Date:2/19/2015

Dallas, TX (PRWEB) February 19, 2015

The clinical trial report “Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015? provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. Irritable bowel syndrome is a general disorder that affects the large intestine. Irritable Bowel Syndrome is one of the most common gastrointestinal disorders; moreover, it has a significant negative impact on a patient’s quality of life and social functioning. That said, IBS is not known to be associated with the development of serious disease or with excess mortality. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Complete report details available @ http://www.rnrmarketresearch.com/irritable-bowel-syndrome-global-clinical-trials-review-h1-2015-market-report.html .

The symptoms of Irritable bowel syndrome may include abdominal pain, bloating, cramping, constipation, gas and diarrhea. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Irritable bowel syndrome.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report also includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Companies discussed in this clinical trials report include GlaxoSmithKline plc, Novartis AG, Actavis plc, Astellas Pharma Inc., Salix Pharmaceuticals Ltd., Ironwood Pharmaceuticals, Inc., AstraZeneca PLC, Ono Pharmaceutical Co., Ltd., Almirall, S.A., A. Menarini Industrie Farmaceutiche Riunite Srl. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=268944 . (This is a premium report priced at US$2500 for a single user License.)

This report also includes the clinical trial overview of top institutes and government that includes Mayo Clinic, University of North Carolina, University of Nottingham, Maastricht University Medical Center, Sahlgrenska University Hospital, Chinese University of Hong Kong, Cedars-Sinai Medical Center, Karolinska Institute, University of California, Los Angeles, Baylor College of Medicine.

“Latest Clinical Trials News on irritable bowel syndrome”: Dec 18, 2014: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation; Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan; Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation; Oct 21, 2014: Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation; Oct 21, 2014: Salix's TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea; Oct 17, 2014: Salix Pharmaceuticals Outlines Data of Rifaximin Presents at American College of Gastroenterology 2014 Annual Scientific Meeting.

Explore more reports on Clinical Trial industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial .

More reports on Clinical Trials:

Steatohepatitis Global Clinical Trials Review, H1, 2015
This report provides elemental information and data relating to the clinical trials on Steatohepatitis. Companies discussed in this steatohepatitis clinical trials report include Genextra S.p.a., Galmed International Ltd., Raptor Pharmaceuticals Corp., Immuron Limited, Genfit SA, Cempra, Inc., Phenex Pharmaceuticals AG, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd., Catalysis, S.L.

Clinical trial overview of top institutes or government includes The National Institute of Diabetes and Digestive and Kidney Diseases, Tehran University of Medical Sciences, University of California, San Diego, Hadassah Medical Organization, Yokohama City University, Institute of Liver and Biliary Sciences, National Nutrition and Food Technology Research Institute, University Health Network, U.S. Department of Veterans Affairs, University of Michigan. Complete report details @ http://www.rnrmarketresearch.com/steatohepatitis-global-clinical-trials-review-h1-2015-market-report.html .

Cholelithiasis Global Clinical Trials Review, H1, 2015
This report provides elemental information and data relating to the clinical trials on Cholelithiasis. Companies and Institutes discussed in this report includes USGI Medical, Inc., Catalysis, S.L., Alternova A/S, University of California, San Diego, Islamic Azad University of Tabriz, Mansoura University, G. Hatzikosta General Hospital, Massachusetts General Hospital, University of California, San Francisco, Universidad Juarez Durango, Hospital Son Llatzer, Kuopio University Hospital, University of Missouri. Complete report details @ http://www.rnrmarketresearch.com/cholelithiasis-global-clinical-trials-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Read the full story at http://www.prweb.com/releases/irritable-bowel-syndrome/clinical-trials-review-h1/prweb12528984.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Experts Issue Guidelines for Treating Irritable Bowel Syndrome
2. MedicationDiscountCard.com Now Helps Sufferers of Irritable Bowel Syndrome
3. Pain treatments less effective for those with irritable bowel
4. Existing medicines show promise for treating stomach and bowel cancer
5. Grape seed promise in fight against bowel cancer
6. Gut microbes spur development of bowel cancer
7. MicroRNA could be key target for bowel cancer treatment
8. Two genes linked to inflammatory bowel disease
9. Wound-healing role for microRNAs in colon offer new insight to inflammatory bowel diseases
10. Growing up on a livestock farm halves the risk of inflammatory bowel diseases
11. Bowel cancer breakthrough may benefit thousands of patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 25, 2017 , ... Somnoware, a leading provider of digital ... module. Using this new feature, sleep physicians can now predict the likelihood of ... airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The Somnoware ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in ... a special report in the May issue of Consumer Reports focused on heart health. ... for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... instrument solutions, announces the continuation of its strategic partnership with and platinum sponsorship ... developing nations in the safe and effective management of complex spine deformity cases, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology: